What triggered AbbVie shares' latest price pullback

Traders Union
All News
Financial News
AbbVie slides 3.30% today to $212.50

Highlights

AbbVie secured a multi-year partnership with Alloy Therapeutics to enhance its antibody discovery platform, signaling ongoing R&D investment.
FY 2026 earnings guidance was set at $14.370–$14.570 EPS, but aesthetics and post-Humira segments continue to face sales and competitive pressures.
ABBV trades below key averages with prevailing bearish momentum, as technicals signal a likely consolidation between $210.83 and $215.22 short term.

Sentiment sours as guidance and segment challenges pressure flows

AbbVie entered a multi-year strategic partnership with Alloy Therapeutics to develop an advanced antibody discovery platform, including upfront and milestone-based financial commitments. The company also provided its FY 2026 earnings guidance at 14.370–14.570 EPS and faced further developments in institutional holdings as some firms adjusted their ABBV positions. Ongoing business challenges were reported in the aesthetics segment, with declining Juvederm sales and continuing management of competition following Humira's loss of exclusivity, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees persistent downward pressure on ABBV. He points to the stock's failure to hold key moving averages and highlights the ongoing losses from Humira's exclusivity and weak aesthetics performance as mounting business risks. Weak momentum and a clear dominance of sellers worsen the technical picture. Recent institutional position adjustments signal eroding confidence. "Without signs of reversal and amid structural headwinds, ABBV faces further downside risk in the near term."

Viktoras Karapetjanc, expert at Traders Union, maintains a constructive stance on ABBV's longer-term outlook. He emphasizes the strategic partnership with Alloy Therapeutics as a positive development for the company’s pipeline and innovation capabilities. Karapetjanc believes institutional activity and management's strong FY 2026 guidance indicate underlying belief in AbbVie's growth story. "I view the recent price action as a temporary setback — the bullish structure remains intact given AbbVie's innovation and forward guidance."

Jainam Mehta, market strategist, notes ABBV is trading near oversold levels after a sharp drop. He sees short-term volatility as an opportunity for tactical range trades, especially within the $210.83–$215.22 band. No clear bullish divergence is setting up yet, but price compressions around support often precede reversals. "If momentum flips near $210.83, contrarian traders might explore rebound setups with tight risk controls."

Oversold signals as bearish bias dominates below key averages

ABBV is trading at $212.50, well below its SMA-20 ($227.73), SMA-50 ($224.27), and just below the longer-term SMA-200 ($214.95). This places the stock under clear short- and medium-term pressure from sellers, while the SMA-200 may act as nearby dynamic support, with the nearest resistance at the Ichimoku Kijun line of $227.58. Momentum signals are mixed, with the MACD showing a neutral stance and a weak ADX suggesting a lack of clear trend. Both D1 and W1 RSI are in sell territory, with CCI and BBP reflecting oversold and negative momentum, meaning sellers are dominating the intraday tone. The AO also supports the bearish bias. ABBV opened lower than the previous close ($219.76 vs. $218.60), creating a small gap, then moved down further by 3.30% to near the lower end of today's range ($209.42–$218.60), indicating high volatility and persistent selling pressure after the open. Despite the oversold conditions, no clear divergence is seen between momentum and oscillator signals; both the daily decline and momentum confirm short-term negative sentiment.

Earlier, analysts noted that despite constructive long-term prospects, AbbVie faced continued selling pressure and persistent volatility following upbeat guidance. The current analysis further reinforces caution, with sustained negative momentum and oversold signals suggesting traders should closely monitor for a potential breakdown below $210.83 as a catalyst for renewed downside risk.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.